Low dose native type II collagen prevents pain in a rat osteoarthritis model

BMC Musculoskeletal Disorders

Volumn 14, Issue , 2013, Pages

  Di Cesare Mannelli, Lorenzo ^a   Micheli, Laura ^a   Zanardelli, Matteo ^a   Ghelardini, Carla ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Articular pain; CTX II; Monoiodoacetate; Oral tolerance

Indexed keywords

BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 2; IODOACETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CARTILAGE DEGENERATION; CONTROLLED STUDY; DRUG EFFICACY; LOCOMOTION; LOW DRUG DOSE; MALE; NOCICEPTIVE STIMULATION; NONHUMAN; OSTEOARTHRITIS; PAIN THRESHOLD; RAT; TREATMENT DURATION; URINALYSIS; WEIGHT BEARING; ANIMAL; DISEASE MODEL; DOSE RESPONSE; PAIN; PATHOLOGY; SPRAGUE DAWLEY RAT; SWINE;

ANIMALS; COLLAGEN TYPE II; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; OSTEOARTHRITIS; PAIN; RATS; RATS, SPRAGUE-DAWLEY; SWINE;

EID: 84880959739     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-14-228     Document Type: Article

References (53)

1. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, Kington RS, Lane NE, Nevitt MC, Zhang Y, Sowers M, McAlindon T, Spector TD, Poole AR, Yanovski SZ, Ateshian G, Sharma L, Buckwalter JA, Brandt KD, Fries JF, Ann Intern Med 2000 133 635 646 10.7326/0003-4819-133-8-200010170-00016 11033593
2. Mechanical factors in articular cartilage and their role in osteoarthritis. Mow VC, Setton LA, Fuilak F, Ratcliffe A, Osteoarthritic disorders Rosemont (IL): American Academy of Orthopaedic Surgeons, Kuettner KE, Goldberg VM, 1995 147 172
3. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. ANON, Arth Rheum 2000 43 1905 1915
4. Articular cartilage and changes in Arthritis: Collagen of articular cartilage. Eyre D, Arthritis Res 2002 4 30 35 11879535
5. Symptomatic and chondroprotective treatment with collagen derivatives in osteoarthritis: a systematic review. Van Vijven JPJ, Luijsterburg PAJ, Verhagen AP, Van Osch GJVM, Kloppenburg M, Bierma-Zeinstra SMA, Osteoarthr Cartil 2012 20 809 821 10.1016/j.joca.2012.04.008 22521757
6. Oral administration of (14)C labelled gelatin hydrolysate leads to an accumulation of radioactivity in cartilage of mice (C57/BL). Oesser S, Adam M, Babel W, Seifert J, J Nutr 1999 129 1891 1895 10498764 (Pubitemid 29468605)
7. Stimulation of type II collagen biosynthesis and secretion in bovine chondrocytes cultured with degraded collagen. Oesser S, Seifert J, Cell Tissue Res 2003 311 393 399 12658447 (Pubitemid 36459678)
8. Disparate efficacy of collagen hydrolysate and glucosamine on the extracellular matrix metabolism of articular chondrocytes. Schunck M, Schulze CH, Oesser S, Osteoarthritis Cartilage 2006 14 114
9. Ingestion of gelatin has differential effect on bone mineral density and body weight in protein undernutrition. Koyama Y, Hirota AH, Irie S, J Nutr Sci Vitaminol 2001 47 84 86 10.3177/jnsv.47.84 11349896 (Pubitemid 32225228)
10. Increase in bone mineral density through oral administration of shark gelatin to ovariectomized rats. Nomura Y, Oohashi K, Watanabe M, Kasugai S, Nutrition 2005 21 1120 1126 10.1016/j.nut.2005.03.007 16308135 (Pubitemid 41674591)
11. Evaluation of the hypotensive potential of bovine and porcine collagen hydrolysates. Faria M, Da Costa EL, Gontijo JAR, Netto FM, J Med Food 2008 11 560 567 10.1089/jmf.2007.0573 18800907
12. Chicken collagen hydrolysate protects rats from hypertension and cardiovascular damage. Zhang Y, Koguchi T, Simizu M, Ohmori T, Takahata Y, Morimatsu F, J Med Food 2010 13 399 405 10.1089/jmf.2009.1246 20170381
13. McCarthy S, Carpenter MR, Barrell MM, Morrissey DE, Jacobson E, Kline G, et al. The effectiveness of gelatine supplementation treatment in individuals with symptoms of mild osteoarthritis. A randomized, doubleblind, placebo-controlled study. US Family Practice News; American Academy of Family Physicians Dallas (TX): Annual Assembly 2000
14. Role of collagen hydrolysate in bone and joint disease. Moskowitz RW, Semin Arthritis Rheum 2000 30 87 99 10.1053/sarh.2000.9622 11071580
15. Change in knee osteoarthritis cartilage detected by delayed gadolinium enhanced magnetic resonance imaging following treatment with collagen hydrolysate: a pilot randomized controlled trial. McAlindon TE, Nuite M, Krishnan N, Ruthazer R, Price LL, Burstein D, Griffith J, Flechsenhar K, Osteoarthr Cartil 2011 19 399 405 10.1016/j.joca.2011.01.001 21251991
16. A multicenter, double blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis. Wei W, Zhang LL, Xu JH, Xiao F, Bao CD, Ni LQ, Li XF, Wu YQ, Sun LY, Zhang RH, Sun BL, Xu SQ, Liu S, Zhang W, Shen J, Liu HX, Wang RC, Arthritis Res Ther 2009 11 180 10.1186/ar2870 19951408
17. Type II collagen oral tolerance; mechanism and role in collagen-induced arthritis and rheumatoid arthritis. Park KS, Park MJ, Cho ML, Kwok SK, Ju JH, Ko HJ, Park SH, Kim HY, Mod Rheumatol 2009 19 581 589 10.1007/s10165-009-0210-0 19697097
18. Anatomical basis of tolerance and immunity to intestinal antigens. Mowat AM, Nat Rev Immunol 2003 3 331 341 10.1038/nri1057 12669023 (Pubitemid 37328685)
19. Dendritic cells in intestinal immune regulation. Coombes JL, Powrie F, Nat Rev Immunol 2008 8 435 446 10.1038/nri2335 18500229 (Pubitemid 351733420)
20. Oral tolerance: Can we make it work? Ilan Y, Hum Immunol 2009 70 768 776 10.1016/j.humimm.2009.06.018 19559742
21. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. Crowley DC, Lau FC, Sharma P, Evans M, Guthrie N, Bagchi M, Bagchi D, Dey DK, Raychaudhuri SP, Int J Med Sci 2009 6 312 321 19847319
22. Mono iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. Guingamp C, Gegout-Pottie P, Philippe L, Terlain B, Netter P, Gillet P, Arthritis Rheum 1997 40 1670 1679 10.1002/art.1780400917 9324022 (Pubitemid 27426161)
23. Development and pharmacological characterization of a rat model of osteoarthritis pain. Pomonis JD, Boulet JM, Gottshall SL, Phillips S, Sellers R, Bunton T, Walker K, Pain 2005 114 339 346 10.1016/j.pain.2004.11.008 15777859 (Pubitemid 40385873)
24. k -opioid agonist produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat. Leighton GE, Rodriguez RE, Hill RG, Hughes J, Br J Pharmacol 1988 93 553 560 10.1111/j.1476-5381.1988.tb10310.x 2836010 (Pubitemid 18073267)
25. Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Sakurai M, Egashira N, Kawashiri T, Yano T, Ikesue H, Oishi R, Pain 2009 147 165 174 10.1016/j.pain.2009.09.003 19782472
26. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman RE, Osteoarthr Cartil 2003 11 821 830 10.1016/S1063-4584(03)00163-8 14609535 (Pubitemid 37407598)
27. The utility of measuring C-terminal telopeptides of collagen type II (CTX-II) in serum and synovial fluid samples for estimation of articular cartilage status in experimental models of destructive joint diseases. Oestergaard S, Chouinard L, Doyle N, Karsdal MA, Smith SY, Qvist P, Tankó LB, Osteoarthritis Cartilage 2006 14 670 679 10.1016/j.joca.2006.01.004 16500121 (Pubitemid 43842730)
28. Joint Inflammation and Early Degeneration Induced by High-Force Reaching Are Attenuated by Ibuprofen in an Animal Model ofWork-RelatedMusculoskeletal Disorder. Driban JB, Barr AE, Amin M, Sitler MR, Barbe MF, J Biomed Biotechnol 2011 2011 691412 10.1155/2011/691412 21403884
29. Effects of Exercise Level on Biomarkers in a Rat Knee Model of Osteoarthritis. Yamaguchi S, Aoyama T, Ito A, Nagai M, Iijima H, Zhang X, Tajino J, Kuroki H, J Orthop Res 2013 31 1026 1031 10.1002/jor.22332 23483591
30. Symmons D, Mathers C, Pfleger B, Global burden of osteoarthritis in the year 2000 Geneva: World Health Organization 2003 http://www.who.int/healthinfo/ paper50.pdf
31. The Australian burden of disease study: measuring the loss of health from diseases, injuries and risk factors. Mathers CD, Vos ET, Stevenson CE, Begg SJ, Med J Aust 2000 172 592 596 10914105 (Pubitemid 30438935)
32. Socioeconomic burden of total joint arthroplasty for symptomatic hip and knee osteoarthritis in the Italian population: a 5-year analysis based on hospitalization records. Piscitelli P, Iolascon G, Di Tanna G, Bizzi E, Chitano G, Argentiero A, Neglia C, Giolli L, Distante A, Gimigliano R, Brandi ML, Migliore A, Arthritis Care Res (Hoboken) 2012 64 1320 1327 10.1002/acr.21706
33. National Arthritis Data Workgroup: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F, Part II. Arthritis Rheum 2008 58 26 35 10.1002/art.23176
34. National Arthritis Data Workgroup: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH, Part I. Arthritis Rheum 2008 58 15 25 10.1002/art.23177
35. Why is osteoarthritis an agerelated disease? Shane Anderson A, Loeser RF, Best Pract Res Clin Rheumatol 2010 24 15 26 20129196
36. World Health Organization, The burden of musculoskeletal conditions at the start of the new millennium Geneva: WHO technical report series 919 2003
37. Italian Statistics Rome, National Institute for Statistics 2005 http://www3.istat.it/dati/catalogo/asi2005/contenuti.html
38. OARSI recommendations for the management of hip and knee osteoarthritis, Part II. OARSI evidence-based, expert consensus guidelines. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P, Osteoarthritis Cartilage 2008 16 137 62 10.1016/j.joca.2007.12.013 18279766 (Pubitemid 351222155)
39. Therapeutic Effects of the Superoxide Dismutase Mimetic Compound Me§ssub§2§esub§DO2A on Experimental Articular Pain in Rats. Di Cesare Mannelli L, Bani D, Bencini A, Brandi ML, Calosi L, Cantore M, Carossino AM, Ghelardini C, Valtancoli B, Failli P, Mediat Inflamm 2013 10.1155/2013/905360
40. Sodium iodoacetate-induced experimental osteoarthritis and associated pain model in rats. Kobayashi K, Imaizumi R, Sumichika H, Tanaka H, Goda M, Fukunari A, Komatsu H, J Vet Med Sci 2003 65 1195 1199 10.1292/jvms.65.1195 14665748 (Pubitemid 41380043)
41. Development of osteoarthritic lesions in mice by "metabolic" and "mechanical" alterations in the knee joints. van der Kraan PM, Vitters EL, van de Putte LB, van den Berg WB, Am J Pathol 1989 135 1001 1014 2556924 (Pubitemid 20026520)
42. Mono-iodoacetate-induced histologic changes in subchondral bone and articular cartilage of rat femorotibial joints: an animal model of osteoarthritis. Guzman RE, Evans MG, Bove S, Morenko B, Kilgore K, Toxicol Pathol 2003 31 619 624 14585729 (Pubitemid 37433471)
43. Local ASIC3 modulates pain and disease progression in a rat model of osteoarthritis. Izumi M, Ikeuchi M, Ji Q, Tani T, J Biomed Sci 2012 19 77 10.1186/1423-0127-19-77 22909215
44. Biological markers in osteoarthritis. Rousseau JC, Delmas PD, Nat Clin Pract Rheumatol 2007 3 346 56 10.1038/ncprheum0508 17538566 (Pubitemid 46864889)
45. Recent progress toward biomarker identification in osteoarthritis. De Ceuninck F, Sabatini M, Pastoureau P, Drug Discovery Today 2011 16 443 449 10.1016/j.drudis.2011.01.004 21262380
46. Urinary collagen type II C-telopeptide fragments are sensitive markers of matrix metalloproteinase-dependent cartilage degradation in rat adjuvant-induced arthritis. De Ceuninck F, Sabatini M, Renoux V, De Nanteuil G, Pastoureau P, J Rheumatol 2003 130 1561 1564 (Pubitemid 36835457)
47. Longitudinal changes of serum COMP and urinary CTX-II predict X-ray defined knee osteoarthritis severity and stiffness in women. Sowers MF, Karvonen-Gutierrez CA, Yosef M, Jannausch M, Jiang Y, Garnero P, Jacobson J, Osteoarthritis Cartilage 2009 17 1609 1614 10.1016/j.joca.2009.06.001 19563924
48. A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis-association with disease progression. Sharif F, Kirwan J, Charni N, Sandell LJ, Whittles C, Garnero P, Rheumatology 2007 46 938 943 10.1093/rheumatology/kel409 17387119 (Pubitemid 47062500)
49. Technology Insight: adult stem cells in cartilage regeneration and tissue engineering. Chen FH, Rousche KT, Tuan RS, Nat Clin Pract Rheumatol 2006 2 373 382 10.1038/ncprheum0216 16932723
50. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Nagler-Anderson C, Bober LA, Robinson ME, Siskind GW, Thorbecke GJ, Proc Natl Acad Sci U S A 1986 83 7443 7446 10.1073/pnas.83.19.7443 3463976 (Pubitemid 16000538)
51. Gut immune system and oral tolerance. Castro-Sánchez P, Martín-Villa JM, Br J Nutr 2013 109 Suppl 2 3 S11 23360879
52. Effects of oral administration of type II collagen on rheumatoid arthritis. Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, Hafler DA, Weiner HL, Science 1993 261 1727 1730 10.1126/science. 8378772 8378772 (Pubitemid 23332920)
53. Goblet cells deliver luminal antigen to CD103+ dendritic cells in the small intestine. McDole JR, Wheeler LW, McDonald KG, Wang B, Konjufca V, Knoop KA, Newberry RD, Miller MJ, Nature 2012 483 345 349 10.1038/nature10863 22422267